

1 **Urinary Metal Levels and Coronary Artery Calcification: Longitudinal Evidence in the**
2 **Multi-Ethnic Study of Atherosclerosis (MESA)**

3
4 **Authors:**

5 Katlyn E. McGraw¹, Kathrin Schilling¹, Ronald A. Glabonjat¹, Marta Galvez-Fernandez¹, Arce
6 Domingo-Relloso², Irene Martinez-Morata¹, Miranda R. Jones^{3,4}, Wendy S. Post^{3,4}, Joel
7 Kaufman⁵, Maria Tellez-Plaza⁶, Linda Valeri², Elizabeth R. Brown^{7,8}, Richard A. Kronmal⁸,
8 Graham R. Barr⁹, Steven Shea⁹, Ana Navas-Acien¹, Tiffany R. Sanchez^{1*}

9
10 **Affiliations:**

11 ¹Columbia University Mailman School of Public Health
12 Department of Environmental Health Science
13 722 W 168th St, New York, NY 10032

14
15 ²Columbia University Mailman School of Public Health
16 Department of Biostatistics
17 722 W 168th St, New York, NY 10032

18
19 ³Johns Hopkins University School of Medicine
20 Department of Oncology
21 Sidney Kimmel Comprehensive Cancer Center
22 Baltimore MD 21057

23
24 ⁴Johns Hopkins University Bloomberg School of Public Health
25 Department of Epidemiology
26 615 N. Wolfe Street. Baltimore MD 212057

27
28 ⁵University of Washington
29 Department of Medicine

30
31 ⁶National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
32 Department of Chronic Diseases Epidemiology

33
34 ⁷Fred Hutchinson Cancer Center
35 Vaccine and Infectious Disease Division

36
37 ⁸University of Washington
38 Department of Biostatistics

39
40 ⁹Columbia University Irving Medical Center
41 Departments of Medicine and Epidemiology

42
43 *** Correspondence:**

44 Katlyn E McGraw, PhD
45 Columbia University Mailman School of Public Health
46 Department of Environmental Health Science
47 722 W 168th St, New York, NY 10032
48 Email: kem2240@cumc.columbia.edu

49
50 **Short Title:** Urinary Metals and CAC Progression in MESA

51 **Total Word Count:** 5,741

52 **ABSTRACT**

53 **Objective:** Growing evidence indicates that exposure to metals are risk factors for
54 cardiovascular disease (CVD). We hypothesized that higher urinary levels of metals with prior
55 evidence of an association with CVD, including non-essential (cadmium, tungsten, and
56 uranium) and essential (cobalt, copper, and zinc) metals are associated with baseline and rate
57 of change of coronary artery calcium (CAC) progression, a subclinical marker of atherosclerotic
58 CVD.

59

60 **Methods:** We analyzed data from 6,418 participants in the Multi-Ethnic Study of Atherosclerosis
61 (MESA) with spot urinary metal levels at baseline (2000-2002) and 1-4 repeated measures of
62 spatially weighted coronary calcium score (SWCS) over a ten-year period. SWCS is a unitless
63 measure of CAC highly correlated to the Agatston score but with numerical values assigned to
64 individuals with Agatston score=0. We used linear mixed effect models to assess the
65 association of baseline urinary metal levels with baseline SWCS, annual change in SWCS, and
66 SWCS over ten years of follow-up. Urinary metals (adjusted to $\mu\text{g/g}$ creatinine) and SWCS were
67 log transformed. Models were progressively adjusted for baseline sociodemographic factors,
68 estimated glomerular filtration rate, lifestyle factors, and clinical factors.

69

70 **Results:** At baseline, the median and interquartile range (25th, 75th) of SWCS was 6.3 (0.7,
71 58.2). For urinary cadmium, the fully adjusted geometric mean ratio (GMR) (95%CI) of SWCS
72 comparing the highest to the lowest quartile was 1.51 (1.32, 1.74) at baseline and 1.75 (1.47,
73 2.07) at ten years of follow-up. For urinary tungsten, uranium, and cobalt the corresponding
74 GMRs at ten years of follow-up were 1.45 (1.23, 1.71), 1.39 (1.17, 1.64), and 1.47 (1.25, 1.74),
75 respectively. For copper and zinc, the association was attenuated with adjustment for clinical
76 risk factors; GMRs at ten years of follow-up before and after adjustment for clinical risk factors
77 were 1.55 (1.30, 1.84) and 1.33 (1.12, 1.58), respectively, for copper and 1.85 (1.56, 2.19) and
78 1.57 (1.33, 1.85) for zinc.

79

80 **Conclusion:** Higher levels of cadmium, tungsten, uranium, cobalt, copper, and zinc, as
81 measured in urine, were associated with subclinical CVD at baseline and at follow-up. These
82 findings support the hypothesis that metals are pro-atherogenic factors.

83

84 **Keywords:** Metals, cardiovascular disease, coronary artery calcification, cadmium, tungsten,
85 uranium, cobalt, copper, zinc, longitudinal, prospective, mixed models

86 **CLINICAL PERSPECTIVE**

87

88 What is new?

- 89 • Urinary levels of non-essential (cadmium, tungsten, uranium) and essential metals
90 (cobalt, copper, zinc) are associated with coronary artery calcification at baseline and at
91 ten years of follow up in a diverse US sample.

92 What are the clinical implications?

- 93 • Reductions in environmental metal exposure may improve cardiovascular health.
94 • Dietary and chelation interventions to reduce metals in the body may improve CVD
95 outcomes.

96

97 **INTRODUCTION**

98

99 Metals are ubiquitous contaminants that affect communities globally.¹ In 2023, supported by
100 epidemiologic and experimental evidence, the American Heart Association established lead,
101 cadmium, and arsenic as cardiovascular disease (CVD) risk factors.² Other metals may also
102 promote atherosclerosis,^{3, 4} an inflammatory process underlying the most common forms of
103 CVD. In the coronary arteries, atherosclerosis induces calcification, which can be measured
104 non-invasively using the Agatston scoring method. Coronary artery calcification (CAC) is highly
105 predictive of coronary heart disease events.⁵ Few studies have investigated the association of
106 metals with CAC, therefore, the role of calcification in metal-related CVD is currently unknown.

107

108 Metals arise from anthropogenic and natural sources and vary geographically. Some are
109 essential while others have no function in humans. Likewise, ambient particulate matter of
110 diameter $\leq 2.5 \mu\text{g}/\text{m}^3$ (PM_{2.5}) is an established risk factor for calcification,⁶ and may be
111 composed of toxic metals.⁷ Metals differ in redox activity and, thus, on the potential toxicity
112 mechanisms.⁸ Cobalt and copper, both essential elements, are examples of redox active metals
113 capable of directly inducing reactive oxygen species, a precursor to the development of CVD.⁹
114 Conversely, the non-essential metal cadmium binds sulfhydryl groups and depletes glutathione,
115 a protective antioxidant.¹⁰ Several metals additionally disrupt the endocrine system¹¹ and target
116 the vascular system,¹² supporting that metals are atherogenic through multiple pathways.

117

118 The main objective of this study is to investigate the longitudinal association of urinary metal
119 levels, biomarkers of metal exposure and internal dose, with changes in spatially weighted
120 calcium scores (SWCS), a measure of CAC that has the advantage of providing numerical
121 scores for individuals with Agatston scores equal to zero¹³ in a multi-ethnic and geographically
122 diverse longitudinal study of adults in the US. We prioritized non-essential (cadmium, tungsten,
123 uranium) and essential (cobalt, copper, zinc) metals that are relevant in US populations and
124 have been previously associated with CVD outcomes.^{3, 4} Other metals that are difficult to
125 interpret in urine (e.g., lead) or in populations with high levels of seafood intake (e.g., arsenic) or
126 for which there is limited evidence of an association with CVD outcomes (e.g., cesium,
127 strontium, manganese) were reported as secondary analyses.

128

129 **METHODS**

130 *Study Population*

131 The Multi-Ethnic Study of Atherosclerosis (MESA) is a multi-center, prospective cohort study of
132 subclinical to clinical CVD.¹⁴ Between July 2000 and August 2002, MESA recruited 6,814
133 participants using community-based strategies at six study sites in Baltimore MD, Chicago IL,
134 Los Angeles CA, New York NY, St. Paul MN, and Winston Salem NC. Participants were free of
135 clinical CVD, men and women aged 45–84 years old from four race and ethnic groups (White,
136 Black, Hispanic/Latino, and Chinese). Data were analyzed for follow-up through MESA Exam 5.
137 Participants completed up to 5 clinic visits (Exam 1 in 2000-2002, Exam 2 in 2002-2004, Exam
138 3 in 2004-2006, Exam 4 in 2005-2007, and Exam 5 in 2010-2012) and 14 follow-up phone calls.
139 All participants gave written informed consent. The Institutional Review Board at each study site
140 approved the study.

141
142 Of the 6,814 MESA participants at baseline, 6,729 had metals and creatinine measured in urine
143 at baseline (Figure S1). We excluded 4 participants with extreme metal values (3 observations
144 for Co, 1 for Cu, 2 for U), as the levels for these participants were 100 times higher than the
145 other highest values in the study. We excluded 32 participants who had a coronary
146 revascularization procedure after exam 1 due to CAC measurement interference and 27
147 participants missing SWCS. Additionally, we excluded 21 participants missing data on
148 education, 69 missing cigarette pack years, 2 missing physical activity, 98 missing low-density
149 lipoprotein cholesterol (LDL), 4 missing diabetes status, 2 missing systolic blood pressure, 38
150 missing estimated glomerular filtration rate (eGFR), and 14 missing lipid lowering and blood
151 pressure medications. The final sample size included a total of 6,418 participants with one or
152 more repeated measures of SWCS for 15,643 observations, including 6,206 at baseline.
153 Approximately 10% of participants (n=950) also had metals measured at Exam 5. Among the
154 6,418 participants in the study after removing missing data, 594 had urinary metal measures
155 available at Exams 1 and 5.

156

157 *Urinary Metals*

158 Spot urine samples were collected during mid to late morning at baseline Exams 1 and 5 using
159 urine cups, aliquoted in small vials, shipped frozen on dry ice to the MESA biorepository, and
160 stored at -80°C. In 2019, aliquots of 0.8mL urine were shipped on dry ice to the Trace Metals
161 Core Laboratory at Columbia University. Detailed information on the analytical protocol to
162 measure metals in MESA have been described elsewhere.¹⁵ Briefly, all metals were analyzed

163 using PerkinElmer NexION 350S Inductively Coupled Plasma Mass Spectrometry with dynamic
164 reaction cell (ICP-DRC-MS) instrument.¹⁶ At least five multi-element standard solutions were
165 used for instrument calibration. The same diluent used for urine samples was used for
166 calibration standards. Metal concentrations of the calibration solutions were chosen to cover the
167 expected ranges of urine analyte concentrations. Samples were analyzed, blinded to
168 participants' characteristics, along with sample preparation blanks, and commercially available
169 certified urine reference materials with a broad range of metal concentrations. Approximately
170 10% of the samples were prepared and measured in duplicate to determine intra-precision, and
171 ~10% were prepared and measured on different days to determine inter-precision. The intra-
172 and inter-assay coefficient of variation ranged from 2.5% for zinc to 14% for uranium, and from
173 5.8% for cadmium to 16% for uranium, respectively (Table S1). Samples below the method
174 detection limit (MDL) were divided by the $\sqrt{2}$. In most urine samples (>95%), the measured
175 elemental concentrations exceeded the MDL except for uranium (11%) and tungsten (32%), see
176 Table S1. To correct for urine dilution, we divided metal concentration by urine creatinine
177 concentration ($\mu\text{g}/\text{creatinine}$), measured using the Jaffe reaction method.¹⁷ For participants with
178 metals analyzed at Exams 1 and 5 (n=594), the intraclass correlation coefficient ranged from
179 0.50 to 0.72 for cobalt and uranium, respectively, supporting that a single baseline metal
180 measure is a good reflection of long-term metal levels.

181
182 *Computed Tomography (cardiac CT) Scanning and Coronary Artery Calcification Measurement*
183 All participants received cardiac CT scans at baseline to measure CAC as previously
184 described.¹⁸ Scans were repeated for nearly all participants between 2002 and 2005, for a
185 subset of participants between 2005 and 2007, and for half of all participants between 2010 and
186 2012. After arterial trajectories across the surface of the heart were determined within 8 mm,
187 and a phantom-based adjustment was applied, candidate calcified plaques were identified by
188 the software with the criteria that each plaque be composed of at least 4 contiguous voxels with
189 an attenuation level of 130 Hounsfield units or greater. A radiologist or cardiologist scored all CT
190 scans using an interactive scoring system at the Harbor-UCLA Los Angeles Biomedical
191 Research Institute by the Agatston method.¹⁸ The Agatston score (AS) reproducibly quantitates
192 CAC from CT images and is highly predictive of coronary heart disease (CHD) and CVD
193 events.¹⁹ CAC-AS is a continuous measure that is dichotomized as 0 and 1 or higher,
194 respectively, for any calcification below or above the threshold.

195

196 *Spatially Weighted Calcium Score*

197 The traditional Agatston score ignores available information in the CT scan due to the
198 conservative but specific algorithm for lesion detection.^{13, 20} Therefore, participants early in the
199 calcification process who do not meet the traditional threshold for the presence of CAC on the
200 CT scan are classified as having a CAC-AS=0. The spatially weighted calcium score (SWCS) is
201 a semi-automated threshold-free CAC scoring method. As described previously,¹³ weights were
202 assigned to each image voxel to calibrate and weight according to the phantom to maximize the
203 CT scan information. Each voxel was assigned a score dependent on the voxel weight and
204 neighboring voxel weight. The detailed algorithm for calculating the SWCS is published.¹³
205 SWCS is a continuous measure of calcification that provides a quantifiable CAC level even
206 when CAC-AS=0, and that is very similar to CAC-AS when it is >0. SWCS predicts incident
207 CHD events even among participants with CAC-AS=0, supporting it is an excellent marker of
208 atherosclerotic CVD risk even at low levels of coronary calcification.²⁰

209

210 *Covariates*

211 Age, sex, race and ethnicity, education, smoking status, physical activity, and use of lipid-
212 lowering and hypertension medications were collected by questionnaire during Exam 1. Race
213 and ethnicity were self-reported and categorized as White, Black, Hispanic/Latino, and Chinese.
214 Study sites included Baltimore MD, Chicago IL, Los Angeles CA, New York NY, St. Paul MN,
215 and Winston Salem NC. Cigarette smoking status was classified as never, former, and current.
216 Participants who had not smoked 100 cigarettes in their lifetime were classified as never
217 smokers. Participants who answered yes were classified as current smokers if they had smoked
218 in the last 30 days or classified as former smokers if they had not smoked in the last 30 days.
219 Cigarette pack-years was calculated by multiplying the intensity in packs per day by duration in
220 years where 20 cigarettes define a pack. Physical activity was defined as the total moderate and
221 high physical activity in hours per week, Monday to Sunday.

222

223 At Exam 1, height and weight were measured to calculate body mass index (BMI, kg/m²).
224 Resting systolic and diastolic blood pressure were measured three times in the seated position
225 using a Dinamap model Pro 100 automated oscillometric sphygmomanometer with the last two
226 measurements averaged for analysis. Low- and high-density lipoprotein cholesterol (LDL, HDL,
227 mg/dL blood), and calibrated fasting plasma glucose (FPG, mg/dL blood), were assessed using
228 standard laboratory techniques. Diabetes mellitus (DM) was defined by the 2003 American
229 Diabetes Association fasting criteria and categorized by normal (<100 mg/dL blood FPG),

230 impaired fasting glucose (100-125 mg/dL blood FPG), untreated and treated diabetes (≥ 126
231 mg/dL blood FPG or taking diabetes medications). eGFR was calculated using the new
232 creatinine and cystatin-C based Chronic Kidney Disease Epidemiology Collaboration equation
233 without accounting for race and ethnicity.²¹ eGFR can influence metal excretion in urine and
234 was therefore used for adjustment in our models. Urinary cotinine, a metabolite of nicotine, was
235 measured by immune assay (Immulite 2000 Nicotine Assay; Diagnostic products Corp., Los
236 Angeles, CA) in a subset of participants (n=3,791). Finally, because air pollution is a source of
237 metal exposure,⁷ average PM_{2.5} ($\mu\text{g}/\text{m}^3$) was estimated using predictions from city-specific
238 spatiotemporal models for calendar years 2000-2001 at baseline.²²

239

240 *Statistical Analysis*

241 We conducted descriptive analyses overall and by participant characteristics of continuous
242 SWCS, dichotomous CAC-AS, and urinary metal levels. Urinary metal levels and SWCS were
243 right skewed and log-transformed for analysis. We performed Spearman correlation tests for
244 log-transformed urinary metals ($\mu\text{g}/\text{g}$ creatinine).

245

246 We used mixed effect models on log-transformed repeated SWCS measures by baseline
247 urinary metal levels with a random intercept on the participant and random slope on the time
248 since baseline cardiac CT scan. By exponentiating the coefficients, the model allows to estimate
249 baseline geometric mean ratios (GMRs), annual GMR change, and GMRs at a relevant time
250 during the follow-up (we selected 10 years) in the average person. Urinary metal levels were
251 modeled as: (1) per interquartile range (IQR) on log-transformed levels (to compare the 75th to
252 the 25th percentile), (2) quartiles (to compare each of the highest three to the lowest quartiles),
253 and (3) log-transformed concentrations with restricted quadratic splines (to evaluate the flexible
254 dose-response relationship). We evaluated the association of baseline metal levels with
255 dichotomous CAC-AS score using a modified Poisson with the generalized linear mixed model
256 to estimate relative risk of incident CAC-AS>0 among participant with CAC-AS=0 at baseline.

257

258 Model 1 was adjusted for sociodemographic (age, sex, race and ethnicity, study site, education)
259 and behavioral factors (smoking status, pack-years, physical activity) and eGFR and BMI.

260 Model 2 was additionally adjusted for cardiovascular risk factors (systolic blood pressure,
261 antihypertensive medications, LDL-cholesterol, HDL-cholesterol, lipid lowering medications, and
262 diabetes status). Because urinary metals levels were measured at baseline, all adjustments
263 were time-invariant covariates acquired at baseline. For the dose-response figures we only

264 show the results for model 2. Finally, we used Wald tests and conducted subgroup analysis to
265 assess effect modification by subgroups of age, sex, race and ethnicity, smoking status, and
266 diabetes status for geometric mean ratios at baseline and at ten years of follow-up.

267

268 *Sensitivity Analyses*

269 We conducted several sensitivity analyses. Because SWCS showed a potential nonlinear
270 relationship with time over the follow-up, we modeled the time since last CT scan as a
271 polynomial. The effect estimates remained unchanged and thus was not used in our final
272 models (not shown). We further adjusted for city-specific average PM_{2.5} at baseline to account
273 for metal exposures originating from ambient air pollution and for potential confounding of the
274 relationship to CAC.⁶ We also further adjusted our models for urinary cotinine to determine
275 whether tobacco use, use of an unaccounted-for nicotine product, or secondhand tobacco
276 exposure is accurately captured by self-reported data. Urinary creatinine levels are commonly
277 used to account for urine dilution but vary by age, sex, and other characteristics. We conducted
278 a sensitivity analysis with adjustment for urine specific gravity instead of using urinary
279 creatinine. Because diabetes status can impact urinary zinc levels, we further adjusted for
280 fasting plasma glucose levels. Finally, in a small subset of participants (n=594), we investigated
281 the relationship between time varying urinary metal levels at two time points, Exams 1 and 5,
282 with repeated measures of SWCS.

283 **RESULTS**

284 The median and interquartile ranges (IQR) [25th, 75th] of SWCS was 6.3 (0.7, 58.2) and CAC-
285 AS>0 occurred in approximately 50% participants at baseline (Table 1). Median and IQR [25th,
286 75th] of SWCS and frequency of positive CAC-AS increased with age and were higher among
287 males, White participants, and those with a high school education or less. Participants who
288 formerly smoked and those who had diabetes mellitus and hypertension had higher median
289 SWCS and frequency of positive CAC-AS.

290

291 Non-essential and essential urinary metal levels varied by participant characteristic (Figure 1).
292 Urinary metal levels (µg/g creatinine) tended to be higher among females, older participants,
293 Chinese participants, and those with less education. Participants from Los Angeles had
294 markedly higher urinary tungsten and uranium levels, and somewhat higher cadmium, cobalt,
295 and copper levels. Cadmium levels were higher among current smokers; the essential metals

296 cobalt and copper were lower among current smokers. Spearman correlation values of urinary
297 metal levels ranged between 0.01 and 0.61 (Figure S2).

298
299 The fully adjusted GMR (95%CI) of SWCS comparing the highest to lowest urinary cadmium
300 quartile was 1.51 (1.32, 1.74) at baseline and 1.75 (1.47, 2.07) at ten years of follow-up; the
301 annual change was positive but not statistically significant (Table 2). The non-linear association
302 apparent in the quartile models was also observed with the restricted quadratic spline models,
303 with clear positive dose-response relationships with SWCS observed for urinary cadmium above
304 0.5 µg/g creatinine both at baseline and at ten years of follow-up (Figure 2).

305
306 For tungsten and uranium, the fully adjusted GMRs (95%CI) of SWCS at baseline comparing
307 the highest to lowest quartiles were 1.13 (1.00, 1.27) and 1.17 (1.04, 1.33); the corresponding
308 GMRs for the annual change were 1.03 (1.00, 1.05) and 1.02 (0.99, 1.04), respectively, and at
309 10 years of follow-up, they were 1.45 (1.23, 1.71) for tungsten and 1.39 (1.17, 1.64) for uranium.
310 The flexible spline models were consistent with a linear dose-response, in particular at ten years
311 of follow-up.

312
313 The fully adjusted GMRs (95%CI) of SWCS at baseline and ten years of follow-up comparing
314 the highest to lowest essential metal quartiles were 1.29 (1.14, 1.47) and 1.47 (1.25, 1.74) for
315 cobalt, 1.15 (1.01, 1.31) and 1.33 (1.12, 1.58) for copper, and 1.54 (1.36, 1.74) and 1.57 (1.33,
316 1.85) for zinc. For the three essential metals, the association with the annual change was not
317 significant (Table 2), and the dose-responses tended to be flat at lower levels and positive at
318 higher levels, especially at ten years (Figure 2). For copper and zinc, there was a marked
319 decline in the association with SWCS both at baseline and at ten years of follow-up after
320 adjusting for clinical risk factors (model 2) compared to model 1. In a post-hoc analysis, this
321 attenuation was largely due to adjustment for diabetes status and fasting plasma glucose
322 (Figure S3), and not to the other variables.

323
324 We conducted several sensitivity analyses. Further adjustment of the association between
325 urinary metals and SWCS for ambient PM_{2.5} resulted in similar effect estimates (Figure S4).
326 Further adjustment for urinary cotinine attenuated the association between urinary cadmium and
327 SWCS, although the association remained significant (Figure S5). Estimates of the association
328 with SWCS were attenuated when urinary metals were adjusted by urinary specific gravity
329 instead of dividing by urinary creatinine, but the general patterns remained (Figure S6).

330
331 Using incident CAC-AS>0 over the follow-up as the study outcome, resulted in consistent
332 associations of non-essential (cadmium, tungsten, uranium) and essential (cobalt, copper, zinc)
333 metals with CAC compared to the SWCS models (Table S2). Models 1 and 2 for the association
334 with SWCS of other non-essential (arsenic, barium, cesium, lead, strontium, thallium) and
335 essential (manganese, molybdenum, selenium) elements available in MESA are reported in
336 Table S3.

337
338 In stratified models by participant subgroups for the priority metals (Table S4), the associations
339 remained similar by age group both at baseline and 10 years for all the metals and no
340 consistent patterns were observed by race and ethnicity with differences for the same metals
341 between baseline and follow-up. By sex the association for cadmium was stronger in women
342 both at baseline and follow-up (p-value for interaction only significant at baseline), while for the
343 other metals the patterns were inconsistent. By smoking status, the association for cadmium
344 and uranium were stronger for former smokers at baseline and follow-up; patterns for other
345 metals were inconsistent.

346
347 Finally, in the small subset of participants with exposure measures at two time points (n=594),
348 the effect estimates were significant and even stronger compared to the main models based on
349 Exam 1 data for urinary cadmium (Table S5), consistent but not significant for tungsten and
350 uranium at ten years of follow-up and for copper at baseline and ten years of follow-up, and
351 inconsistent but not significant for cobalt and zinc.

352 **DISCUSSION**

353
354 In this longitudinal study of coronary atherosclerosis progression among multi-ethnic adults from
355 six urban areas in the United States, we found that baseline urinary levels of the non-essential
356 metals: cadmium, uranium, and tungsten, and essential metals: cobalt, copper, and zinc were
357 associated with CAC, an established subclinical marker of CVD risk, at ten-years of follow-up.
358 Among the non-essential metals, tungsten and uranium were significantly associated with
359 annual changes in SWCS and with stronger associations at the ten years follow-up compared to
360 baseline, while for cadmium the association at baseline and the 10 years follow-up remained
361 similar. For copper and zinc, a marked attenuation of the association with SWCS was observed
362 after adjustment for clinical risk factors, in particular diabetes and fasting plasma glucose. Taken

363 together, these results support that metal exposure and/or metabolism, as measured in urine,
364 contributes to the progression of atherosclerosis as measured by coronary calcification in
365 diverse adults across the US.

366

367 Non-essential Metals

368

369 *Cadmium, Cd*

370 Cadmium is a highly toxic and carcinogenic metal that has been associated with clinical CVD
371 outcomes in numerous studies.^{2, 23, 24} In MESA, higher levels of urinary cadmium were
372 associated with higher SWCS both at baseline and after ten-years of follow-up. The association
373 with annual changes in SWCS, although positive, was not statistically significant. These findings
374 are potentially related to the long-half life and thus urinary cadmium, which reflects the
375 cumulative body burden. A meta-analysis of 12 prospective studies comparing the highest to
376 lowest cadmium exposure categories and clinical CVD reported pooled relative risk of 1.36
377 (95% CI: 1.11-1.66) for urine.²⁵ Proposed mechanisms by which cadmium affects the
378 vasculature include impaired nitric oxide functioning and signaling,²⁶ modulated calcium
379 concentrations,²⁷ endothelial cell apoptosis,²⁸ and oxidative stress through glutathione depletion
380 and other mechanisms.²⁹ In Swedish adults (n=5,627), blood cadmium levels were cross-
381 sectionally associated with the prevalence of CAC-AS>0 (prevalence ratio 1.25, 95% CI: 1.13,
382 1.38).³⁰ Although results were similar, our study uses urinary cadmium, which has a longer half-
383 life than blood cadmium. Tobacco smoke is the main source of cadmium followed by
384 contaminated foods due to widespread soil pollution from the use of phosphate fertilizers rich in
385 cadmium, production and disposal of nickel-cadmium batteries, and other industrial uses.³¹ We
386 found consistent, although attenuated associations between urinary cadmium and SWCS in
387 never smokers in MESA, which is consistent with findings for the association with incident CVD
388 among never smokers in the above cited meta-analysis (pooled relative risk 1.27, 95% CI: 0.97,
389 1.67).

390

391 *Tungsten, W*

392 Tungsten is widespread in drinking water in the Western United States, used in welding, oil
393 production, and electrical and aerospace industries, and exists in the particulate phase in
394 ambient air due to low vapor pressure.³² Urinary tungsten levels have been associated with
395 PM_{2.5} previously in MESA.³³ Some prior but limited evidence has related tungsten with
396 cardiovascular outcomes. In NHANES, urinary tungsten levels were associated with stroke

397 prevalence,³⁴ composite cardiovascular and cerebrovascular disease,³⁵ and higher self-reported
398 CVD.³⁶ In the Strong Heart Study, increasing baseline urinary tungsten was not associated with
399 incident CVD (n=2,726).³⁷ Our sensitivity analyses found a slight attenuation on the association
400 of tungsten with SWCS at follow-up when further adjusting for PM_{2.5}. Together these findings
401 support that urinary tungsten levels contribute to the progression of atherosclerosis and that
402 ambient air pollution may be a relevant source of tungsten. Additional studies are needed to
403 evaluate the role of tungsten in atherosclerosis and clinical CVD, including relevant modifiers
404 and confounders like PM_{2.5}.

405

406 *Uranium, U*

407 Uranium is present in groundwater, is used for nuclear energy production, and is often found in
408 phosphate fertilizers due to uranium in the phosphate rock used for fertilizer manufacturing.³⁸
409 Uranium exposure likely comes from groundwater contamination, which is federally regulated at
410 a maximum contaminant level of 30 µg/L in drinking water. Previous experimental and
411 epidemiological evidence of uranium exposure and CVD is limited.⁸ Three studies of enriched
412 uranium miners found increased risk for CHD risk at three recruitment sites in the United
413 States,³⁹ increased risk for angina in New Mexico,⁴⁰ and increased CVD mortality in France.⁴¹ In
414 NHANES 2007-2008 (n=1,857), urinary uranium levels were not associated with self-reported
415 congestive heart failure, CHD, angina, heart attack, or stroke.⁴² In the Strong Heart Family
416 Study, a cohort of American Indians in the Southwest and Great Plains, urinary uranium levels
417 were associated with hypertension, a major CVD risk factor.⁴³ In MESA, urinary uranium levels
418 were highest in participants from Los Angeles, CA. These findings indicate that uranium may be
419 a significant contributor to CVD, specifically for those exposed to higher levels of uranium in the
420 Midwest and Southwest regions. Additional research is needed to further evaluate the role of
421 uranium in atherosclerosis and CVD development.

422

423 Essential Metals

424 *Cobalt, Co*

425 Cobalt is an essential metal with strong ligand binding properties, low mobility, and integral as
426 the central ion in the coenzyme vitamin B12 necessary for protein synthesis and homocysteine
427 methylation.⁴⁴ Cobalt is used in glass, inks, paints, and the heavy metal industry.⁴⁵ Cobalt has
428 been linked to non-ischemic cardiomyopathy and has experimentally shown both beneficial and
429 deleterious effects to the cardiovascular system.⁴⁵ Cobalt interferes with calcium binding and
430 transport, interrupts ATP generation and production, and produces reactive oxygen species.⁴⁵ In

431 our study, we found that urinary cobalt levels were significantly associated with SWCS when
432 comparing the two highest urinary cobalt quartiles to the lowest. In the Horteiga study, a
433 population-based cohort study from Spain, urinary cobalt levels were not associated with CVD
434 risk⁴ or oxidative stress biomarkers⁴⁶ at low levels. Our findings suggest that higher urinary
435 cobalt levels may contribute to CAC, warranting further investigation.

436

437 *Copper, Cu*

438 Copper is an essential element necessary as a catalytic or structural cofactor, necessary for the
439 regulation of oxidative stress and has been linked to CVD, particularly coronary heart disease,
440 both when levels are deficient and in excess.⁴⁷ Copper is widely used in agriculture as
441 algaecides, herbicides, pesticides, wood preservation, water treatment, wiring, plumbing, and
442 cookware.⁴⁸ Several studies have shown PM_{2.5} composed of copper is significantly associated
443 with increased risk of CVD and CHD,⁴⁹ and cardiovascular mortality.⁵⁰ A recent meta-analysis of
444 35 studies found that the pooled relative risk comparing the highest to lowest copper exposure
445 tertiles was 1.81 (95% CI: 1.05, 3.11) for incident CVD and 2.22 (95%CI: 1.31, 3.74) for incident
446 coronary heart disease.²³ In the Horteiga study, higher urinary copper levels were associated
447 with higher CVD risk,⁴ but not with oxidative stress biomarkers.⁴⁶ The association of urinary
448 copper levels with SWCS at baseline and ten years of follow-up in MESA was attenuated after
449 adjustment for CVD risk factors, with the majority of attenuation related to diabetes status.
450 Deficient Cu levels cause increased susceptibility to LDL and HDL oxidation, a primary
451 mechanism in the development of atherosclerosis.⁵¹ Excess copper can induce oxidative stress
452 and produce reactive oxygen species, and the formation of a copper-homocysteine complex
453 that can contribute to endothelial dysfunction and vascular injury.²³ Although most previous
454 studies have linked blood copper to CVD, our study shows that urinary copper levels are also
455 linked to higher levels of CAC.

456

457 *Zinc, Zn*

458 Zinc is an essential element best known for its key roles in the regulation of oxidative stress, is
459 also required for superoxide dismutase and in pancreatic islet physiology, as insulin is a
460 hexamer made up of two zinc ions and one calcium ion. The association of urinary zinc levels
461 with SWCS at baseline and ten years of follow-up were attenuated when adjusting for
462 cardiovascular risk factors, including diabetes. Because zinc is an essential metal necessary for
463 catalytic, structural, and regulatory metabolism,⁵² altered zinc homeostasis by changes in
464 cellular zinc concentrations is an important marker of a disease state. Zinc deficiency in serum

465 and increased urinary zinc levels have been proposed as indicators of the development of CVD
466 and diabetes.⁵³ Urinary zinc levels have been associated with oxidative stress markers⁴⁶ and
467 CVD incidence in the Hortega Study.⁴⁶ Likewise, changes in cellular and free zinc ion
468 concentrations can enhance oxidative stress.⁵² Our findings support previous evidence that
469 urinary zinc levels are associated with CVD through increasing CAC. This may be due to higher
470 urinary zinc levels among individuals with diabetes, a primary risk factor for CVD.

471

472 *Clinical and Public Health implications*

473 Our findings suggest that metals, both essential and non-essential, are related to the
474 development of CVD at least in part through increased arterial calcification. Growing evidence
475 from clinical trials supports that metal chelation can be beneficial for improving CVD outcomes
476 in populations with cardiovascular disease, which could be explained by the role of chelating
477 agents reducing non-essential metal accumulation in the body and by improving homeostasis of
478 essential metals.^{54, 55} Given the importance of metal exposure with CVD, as supported in this
479 study, further investigation in other large, longitudinal studies with data on CAC is necessary to
480 further characterize this association across multiple populations, in particular to evaluate
481 potential gene-environment interactions, characterize associations for subgroups of the
482 population, and inform relevant interventions. These findings also provide additional support for
483 public health actions from governments and public health agencies to lower acceptable limits of
484 metals in air, water, and soil and improve enforcement of metal pollution reduction, particularly
485 in communities experiencing disproportionate metal exposures.² Public health interventions to
486 reduce metal exposure may contribute to reducing CVD mortality, the leading cause of death
487 across the globe, as supported by previous studies on the impact of lead reductions in
488 reductions of CVD incident rates in the United States.²⁴

489

490

491 *Strengths and Limitations*

492 This is a large, longitudinal study of metal exposure and subclinical CVD. Our study presents
493 new evidence of the link between urinary biomarkers of cadmium and less studied tungsten,
494 uranium, cobalt, copper, and zinc. Few studies of metals have assessed CAC, and most are
495 cross-sectional. We assessed CAC prospectively to estimate changes in calcification using
496 repeated measures of CAC, which allows to assess the association with calcification over time.
497 To address the limitations of the dichotomized CAC-AS, we used SWCS, a more sensitive and
498 continuous marker of calcification to maximize the available data.²⁰ Our study has several

499 limitations. Although urinary metal levels were measured in 10% of participants at Exams 1 and
500 5, we used urinary metal levels measured at baseline to increase power in our analysis and
501 because levels across both exams supported that a single metal measure reflects long-term
502 exposure and internal dose. In an exploratory analysis of the participants with time varying
503 exposure measured at Exams 1 and 5, results were largely consistent. Residual and unknown
504 confounding are possible, although we employed multiple sensitivity analyses using measures
505 of ambient pollution and urinary cotinine, as well as by accounting for urine dilution using
506 specific gravity as an alternative approach.

507

508 *Conclusions*

509 In this prospective study of subclinical CVD across diverse urban US communities, we found that
510 non-essential metals cadmium, tungsten, uranium, and essential metals cobalt, copper and
511 zinc, as measured in urine, were associated with levels of CAC at baseline and over a ten year
512 period. These findings support that atherosclerosis and resulting calcification contribute to
513 explain the association of metals with clinical CVD outcomes. Incorporating the prevention and
514 management of metal exposure and internal dose into clinical and public health guidelines
515 provides novel strategies for the prevention and treatment of cardiovascular disease.

516

517 **SOURCES OF FUNDING**

518 The Multi-Ethnic Study of Atherosclerosis (MESA) is supported by contracts 75N92020D00001,
519 HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002,
520 N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163,
521 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-
522 HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood
523 Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the
524 National Center for Advancing Translational Sciences (NCATS). This publication was developed
525 under the Science to Achieve Results (STAR) research assistance agreements, No. RD831697
526 (MESA Air) and RD-83830001 (MESA Air Next Stage), awarded by the U.S Environmental
527 Protection Agency (EPA). It has not been formally reviewed by the EPA. The views expressed
528 in this document are solely those of the authors and the EPA does not endorse any products or
529 commercial services mentioned in this publication. Dr. Maria Tellez-Plaza was supported by
530 grants PI15/00071 and PI22/00029 from the Strategic Action for Health Research, Instituto de
531 Salud Carlos III and the Spanish Ministry of Science and Innovation, and co-funded with

532 European Funds for Regional Development (FEDER). The opinions and views expressed in this
533 article are those of the authors and do not necessarily represent the official position of the
534 Instituto de Salud Carlos III (Spain). Work in the authors' laboratories is also supported in part
535 by NIH grants P42ES023716, P42ES010349, P42ES033719, P30ES009089, T32ES007322,
536 R01ES029967, R01HL155576. The authors thank the other investigators, the staff, and the
537 participants of the MESA study for their valuable contributions. A full list of participating MESA
538 investigators and institutions can be found at <http://www.mesa-nhlbi.org>. This paper has been
539 reviewed and approved by the MESA Publications and Presentations Committee.

540

541 DISCLOSURES

542 The authors have no conflict of interest to disclose.

543

544 The views expressed in this manuscript are those of the authors and do not necessarily
545 represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of
546 Health; or the U.S. Department of Health and Human Services.

547 REFERENCES

548

- 549 1. Martinez-Morata I, Sobel M, Tellez-Plaza M, Navas-Acien A, Howe CG, Sanchez TR. A state-of-
550 the-science review on metal biomarkers. *Current Environmental Health Reports*. 2023:1-35
- 551 2. Lamas GA, Bhatnagar A, Jones MR, Mann KK, Nasir K, Tellez-Plaza M, et al. Contaminant
552 metals as cardiovascular risk factors: A scientific statement from the american heart association.
553 *Journal of the American Heart Association*. 2023:e029852
- 554 3. Grau-Perez M, Caballero-Mateos MJ, Domingo-Relloso A, Navas-Acien A, Gomez-Ariza JL,
555 Garcia-Barrera T, et al. Toxic metals and subclinical atherosclerosis in carotid, femoral, and
556 coronary vascular territories: The aragon workers health study. *Arterioscler Thromb Vasc Biol*.
557 2022;42:87-99
- 558 4. Domingo-Relloso A, Grau-Perez M, Briongos-Figuero L, Gomez-Ariza JL, Garcia-Barrera T,
559 Dueñas-Laita A, et al. The association of urine metals and metal mixtures with cardiovascular
560 incidence in an adult population from spain: The hortega follow-up study. *International Journal of*
561 *Epidemiology*. 2019;48:1839-1849
- 562 5. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a
563 predictor of coronary events in four racial or ethnic groups. *New England Journal of Medicine*.
564 2008;358:1336-1345
- 565 6. Kaufman JD, Adar SD, Barr RG, Budoff M, Burke GL, Curl CL, et al. Association between air
566 pollution and coronary artery calcification within six metropolitan areas in the USA (the multi-
567 ethnic study of atherosclerosis and air pollution): A longitudinal cohort study. *Lancet (London,*
568 *England)*. 2016;388:696-704
- 569 7. Wang M, Beelen R, Stafoggia M, Raaschou-Nielsen O, Andersen ZJ, Hoffmann B, et al. Long-
570 term exposure to elemental constituents of particulate matter and cardiovascular mortality in 19
571 european cohorts: Results from the escape and transphorm projects. *Environ Int*. 2014;66:97-106
- 572 8. Nigra AE, Ruiz-Hernandez A, Redon J, Navas-Acien A, Tellez-Plaza M. Environmental metals
573 and cardiovascular disease in adults: A systematic review beyond lead and cadmium. *Curr*
574 *Environ Health Rep*. 2016;3:416-433

- 575 9. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. *Toxicology*.
576 2011;283:65-87
- 577 10. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. *Curr Med Chem*.
578 2005;12:1161-1208
- 579 11. Iavicoli I, Fontana L, Bergamaschi A. The effects of metals as endocrine disruptors. *J Toxicol*
580 *Environ Health B Crit Rev*. 2009;12:206-223
- 581 12. Prozialeck WC, Edwards JR, Nebert DW, Woods JM, Barchowsky A, Atchison WD. The vascular
582 system as a target of metal toxicity. *Toxicol Sci*. 2008;102:207-218
- 583 13. Liang CJ, Budoff MJ, Kaufman JD, Kronmal RA, Brown ER. An alternative method for quantifying
584 coronary artery calcification: The multi-ethnic study of atherosclerosis (mesa). *BMC Medical*
585 *Imaging*. 2012;12:14
- 586 14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study
587 of atherosclerosis: Objectives and design. *Am J Epidemiol*. 2002;156:871-881
- 588 15. Schilling K GR, Balac O, Gálvez-Fernández M, Slavkovich V, Goldsmith J, Jones MR, Sanchez
589 TR, Navas-Acien A. Method validation for (ultra)-trace element concentrations in urine for small
590 sample volumes in large epidemiological studies: Application to the population-based
591 epidemiological multi-ethnic study of atherosclerosis (mesa). 2023;Under Review
- 592 16. Nixon D, Eckdahl S, Butz J, Burrit M, Neubauer K, Schneider C. Determination of arsenic, lead,
593 cadmium, and mercury in whole blood and urine using dynamic reaction cell icp-ms. *Application*
594 *Notes, Perkin-Elmer SCIEX Instruments*.
- 595 17. Jaffe M. Ueber den niederschlag, welchen pikrinsäure in normalem harn erzeugt und über eine
596 neue reaction des kreatinins. 1886;10:391-400
- 597 18. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR, Jr., et al. Calcified coronary
598 artery plaque measurement with cardiac ct in population-based studies: Standardized protocol of
599 multi-ethnic study of atherosclerosis (mesa) and coronary artery risk development in young adults
600 (cardia) study. *Radiology*. 2005;234:35-43
- 601 19. Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of
602 cardiovascular disease. *BMJ*. 2021;373:n776
- 603 20. Shea S, Navas-Acien A, Shimbo D, Brown ER, Budoff M, Bancks MP, et al. Spatially weighted
604 coronary artery calcium score and coronary heart disease events in the multi-ethnic study of
605 atherosclerosis. *Circulation: Cardiovascular Imaging*. 2021;14:e011981
- 606 21. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and
607 cystatin c–based equations to estimate gfr without race. *New England Journal of Medicine*.
608 2021;385:1737-1749
- 609 22. Kirwa K, Szpiro AA, Sheppard L, Sampson PD, Wang M, Keller JP, et al. Fine-scale air pollution
610 models for epidemiologic research: Insights from approaches developed in the multi-ethnic study
611 of atherosclerosis and air pollution (mesa air). *Curr Environ Health Rep*. 2021;8:113-126
- 612 23. Chowdhury R, Ramond A, O’Keeffe LM, Shahzad S, Kunutsor SK, Muka T, et al. Environmental
613 toxic metal contaminants and risk of cardiovascular disease: Systematic review and meta-
614 analysis. *BMJ*. 2018;362:k3310
- 615 24. Ruiz-Hernandez A, Navas-Acien A, Pastor-Barriuso R, Crainiceanu CM, Redon J, Guallar E, et
616 al. Declining exposures to lead and cadmium contribute to explaining the reduction of
617 cardiovascular mortality in the us population, 1988–2004. *International journal of epidemiology*.
618 2017;46:1903-1912
- 619 25. Tellez-Plaza M, Jones MR, Dominguez-Lucas A, Guallar E, Navas-Acien A. Cadmium exposure
620 and clinical cardiovascular disease: A systematic review. *Curr Atheroscler Rep*. 2013;15:356
- 621 26. Majumder S, Muley A, Kolluru GK, Saurabh S, Tamilarasan K, Chandrasekhar S, et al. Cadmium
622 reduces nitric oxide production by impairing phosphorylation of endothelial nitric oxide synthase.
623 *Biochemistry and cell biology*. 2008;86:1-10
- 624 27. Biagioli M, Pifferi S, Raghianti M, Bucci S, Rizzuto R, Pinton P. Endoplasmic reticulum stress
625 and alteration in calcium homeostasis are involved in cadmium-induced apoptosis. *Cell calcium*.
626 2008;43:184-195
- 627 28. Lin H-C, Hao W-M, Chu P-H. Cadmium and cardiovascular disease: An overview of
628 pathophysiology, epidemiology, therapy, and predictive value. *Revista Portuguesa de*
629 *Cardiologia*. 2021;40:611-617

- 630 29. Ruiz-Hernandez A, Kuo CC, Rentero-Garrido P, Tang WY, Redon J, Ordovas JM, et al.
631 Environmental chemicals and DNA methylation in adults: A systematic review of the
632 epidemiologic evidence. *Clin Epigenetics*. 2015;7:55
- 633 30. Barregard L, Sallsten G, Harari F, Andersson EM, Forsgard N, Hjelmgren O, et al. Cadmium
634 exposure and coronary artery atherosclerosis: A cross-sectional population-based study of
635 swedish middle-aged adults. *Environ Health Perspect*. 2021;129:67007
- 636 31. Cullen JT, Maldonado MT. Biogeochemistry of cadmium and its release to the environment. *Met
637 ions Life Sci*. 2013;11:31-62
- 638 32. EPA (U.S. Environmental Protection Agency). Proceedings of the technical workshops for the
639 hydraulic fracturing study: Chemical & analytical methods. 2011
- 640 33. Pang Y, Jones MR, Tellez-Plaza M, Guallar E, Vaidya D, Post WS, et al. Association of
641 geography and ambient air pollution with urine metal concentrations in six us cities: The multi-
642 ethnic study of atherosclerosis. *Int J Environ Res Public Health*. 2016;13
- 643 34. Tyrrell J, Galloway TS, Abo-Zaid G, Melzer D, Depledge MH, Osborne NJ. High urinary tungsten
644 concentration is associated with stroke in the national health and nutrition examination survey
645 1999–2010. *PloS one*. 2013;8:e77546
- 646 35. Agarwal S, Zaman T, Murat Tuzcu E, Kapadia SR. Heavy metals and cardiovascular disease:
647 Results from the national health and nutrition examination survey (nhanes) 1999-2006.
648 *Angiology*. 2011;62:422-429
- 649 36. Guo X, Li N, Wang H, Su W, Song Q, Liang Q, et al. Combined exposure to multiple metals on
650 cardiovascular disease in nhanes under five statistical models. *Environmental Research*.
651 2022;215:114435
- 652 37. Nigra AE, Howard BV, Umans JG, Best L, Francesconi KA, Goessler W, et al. Urinary tungsten
653 and incident cardiovascular disease in the strong heart study: An interaction with urinary
654 molybdenum. *Environmental Research*. 2018;166:444-451
- 655 38. Schnug E, Lottermoser BG. Fertilizer-derived uranium and its threat to human health.
656 *Environmental Science & Technology*. 2013;47:2433-2434
- 657 39. Anderson JL, Bertke SJ, Yiin J, Kelly-Reif K, Daniels RD. Ischaemic heart and cerebrovascular
658 disease mortality in uranium enrichment workers. *Occup Environ Med*. 2021;78:105-111
- 659 40. Al Rashida VJM, Wang X, Myers OB, Boyce TW, Kocher E, Moreno M, et al. Greater odds for
660 angina in uranium miners than nonuranium miners in new mexico. *J Occup Environ Med*.
661 2019;61:1-7
- 662 41. Drubay D, Ca, xeb, r-Lorho S, Laroche P, Laurier D, et al. Mortality from circulatory system
663 diseases among french uranium miners: A nested case-control study. *Radiat Res*. 2015;183:550-
664 562
- 665 42. Mendy A, Gasana J, Vieira ER. Urinary heavy metals and associated medical conditions in the us
666 adult population. *Int J Environ Health Res*. 2012;22:105-118
- 667 43. Gold AON-A, Ana. Assessment of differential uranium exposure and its association with
668 hypertension and elevated blood pressure in american indian communities in the strong heart
669 family study. 2023;2023
- 670 44. Jomova K, Makova M, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, et al. Essential metals in
671 health and disease. *Chemico-Biological Interactions*. 2022;367:110173
- 672 45. Packer M. Cobalt cardiomyopathy. *Circulation: Heart Failure*. 2016;9:e003604
- 673 46. Domingo-Relloso A, Grau-Perez M, Galan-Chilet I, Garrido-Martinez MJ, Tormos C, Navas-Acien
674 A, et al. Urinary metals and metal mixtures and oxidative stress biomarkers in an adult population
675 from spain: The hortega study. *Environment International*. 2019;123:171-180
- 676 47. Klevay LM. Cardiovascular disease from copper deficiency--a history. *J Nutr*. 2000;130:489s-
677 492s
- 678 48. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for copper.
679 2022
- 680 49. Badaloni C, Cesaroni G, Cerza F, Davoli M, Brunekreef B, Forastiere F. Effects of long-term
681 exposure to particulate matter and metal components on mortality in the rome longitudinal study.
682 *Environ Int*. 2017;109:146-154
- 683 50. Lavigne A, Freni Sterrantino A, Liverani S, Blangiardo M, de Hoogh K, Molitor J, et al.
684 Associations between metal constituents of ambient particulate matter and mortality in england:
685 An ecological study. *BMJ Open*. 2019;9:e030140

- 686 51. James JD, Dennis M, James HOK. Copper deficiency may be a leading cause of ischaemic heart
687 disease. *Open Heart*. 2018;5:e000784
- 688 52. Maret W. Zinc in pancreatic islet biology, insulin sensitivity, and diabetes. *Prev Nutr Food Sci*.
689 2017;22:1-8
- 690 53. Galvez-Fernandez M, Powers M, Grau-Perez M, Domingo-Relloso A, Lolacono N, Goessler W, et
691 al. Urinary zinc and incident type 2 diabetes: Prospective evidence from the strong heart study.
692 *Diabetes Care*. 2022;45:2561-2569
- 693 54. Ravalli F, Vela Parada X, Ujueta F, Pinotti R, Anstrom KJ, Lamas GA, et al. Chelation therapy in
694 patients with cardiovascular disease: A systematic review. *Journal of the American Heart*
695 *Association*. 2022;11:e024648
- 696 55. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, et al. Effect of disodium edta
697 chelation regimen on cardiovascular events in patients with previous myocardial infarction: The
698 tact randomized trial. *Jama*. 2013;309:1241-1250
- 699

700 **TABLES AND FIGURES**

701
 702 **Table 1.** Median and interquartile ranges [25th, 75th] of spatially weighted calcium scores
 703 (SWCS) and corresponding number (%) of positive coronary artery calcification Agatston scores
 704 (CAC-AS) overall and by participant characteristic at baseline exam 1 (2000-2002).
 705

	n	SWCS	CAC-AS ≥ 1
Overall	6,206	6.3 [0.7, 58.2]	3,080 (49.6)
Age (Years)			
<55	1,758	1.5 [0.3, 7.1]	429 (24.4)
55-64	1,716	4.4 [0.6, 31.7]	759 (44.2)
≥65	2,732	30.2 [2.9, 162.4]	1,892 (69.3)
Sex (%)			
Female	3,284	2.9 [0.4, 23.8]	1,302 (39.6)
Male	2,922	17.1 [2, 117.9]	1,778 (60.8)
Race and Ethnicity (%)			
White	2,375	8.8 [0.7, 102.3]	1,349 (56.8)
Black	1,706	5.6 [0.8, 36.2]	741 (43.4)
Hispanic/Latino	1,360	6 [1.4, 45]	609 (44.8)
Chinese	765	3.1 [0.3, 45.9]	381 (49.8)
Study Site (%)			
Salem, NC	960	2.1 [0.1, 50]	489 (50.9)
New York, NY	994	6.7 [1.3, 35.7]	412 (41.4)
Baltimore, MD	955	10.2 [1.3, 89.3]	532 (55.7)
St. Paul, MN	972	5.7 [1.6, 76.4]	496 (51)
Chicago, IL	1,112	6.2 [0.5, 52.4]	534 (48)
Los Angeles, CA	1,213	8.7 [0.8, 56.8]	617 (50.9)
Education (%)			
High School or Less	2,226	8.1 [1.2, 65.9]	1,169 (52.5)
Some College	1,450	6.5 [0.8, 57.8]	702 (48.4)
College Degree or More	2,530	4.8 [0.5, 49.7]	1,209 (47.8)
Smoking Status (%)			
Never	3,165	4.3 [0.5, 37.4]	1,400 (44.2)
Former	2,248	12.1 [1.3, 92.4]	1,296 (57.7)
Current	793	4.7 [0.7, 51.9]	384 (48.4)
Pack-Years			
0	3,250	4.3 [0.5, 37.1]	1,431 (44)
1 - 10	1,084	5.8 [0.9, 52.5]	515 (47.5)
11 - 20	604	8.9 [1, 63.7]	322 (53.3)
>20	1,268	18.3 [1.5, 141.8]	812 (64)
BMI (kg/			
BMI < 25	1,810	2.2 [0.2, 51.2]	862 (47.6)
25 ≤ BMI < 30	2,432	5.6 [0.8, 62.2]	1,252 (51.5)
BMI ≥ 30	1,964	11.3 [2.3, 58.8]	966 (49.2)

Physical Activity (MET-hours/week)			
≤34	1,625	9 [0.9, 62.9]	846 (52.1)
35-69	1,563	6.9 [0.7, 65.5]	816 (52.2)
70-139	1,691	6.1 [0.7, 60.4]	830 (49.1)
≥140	1,327	4.5 [0.6, 37]	588 (44.3)
LDL-cholesterol (mg/dL)			
<100	1,794	5.6 [0.6, 60]	865 (48.2)
100-129	2,414	6.5 [0.7, 56.3]	1,183 (49)
130-159	1,435	6.3 [0.8, 58.6]	725 (50.5)
≥160	563	7.3 [1.1, 62.2]	307 (54.5)
HDL-cholesterol (mg/dL)			
<50	3,238	10 [1.3, 71.2]	1,750 (54)
50-69	2,287	4.5 [0.5, 43.3]	1,047 (45.8)
70-99	625	2 [0.2, 31.5]	256 (41)
≥100	56	3.8 [0.3, 51.6]	27 (48.2)
eGFR (mL/min/1.73 m ²)			
<45	55	81.5 [20, 230.6]	44 (80)
45-59	140	55.8 [4.9, 293.2]	107 (76.4)
60-89	1,739	23.1 [2.6, 134.8]	1,141 (65.6)
>90	4,272	3.6 [0.5, 30.1]	1,788 (41.9)
Diabetes Mellitus (%)			
Normal	4,602	4.3 [0.5, 43.3]	2,124 (46.2)
IFG	849	12.6 [1.9, 84.1]	483 (56.9)
DM	755	22.1 [3.4, 151.6]	473 (62.6)
Hypertension (%)			
No	3,415	3 [0.4, 27.2]	1,398 (40.9)
Yes	2,791	17.2 [1.9, 110.5]	1,682 (60.3)
BP Medications (%)			
No	3,897	3.6 [0.5, 32.6]	1,681 (43.1)
Yes	2,309	18.1 [2, 113.7]	1,399 (60.6)
Lipid Medications (%)			
No	5,186	5 [0.6, 45.8]	2,400 (46.3)
Yes	1,020	23 [2, 144.7]	680 (66.7)
PM _{2.5} (µg/m ³)			
≤12	913	6.1 [1.6, 83.3]	473 (51.8)
13-15	264	5.5 [0.6, 45.6]	125 (47.3)
16-20	3,707	6.3 [0.6, 57.4]	1,820 (49.1)
>20	1,063	8.7 [0.8, 57.2]	547 (51.5)

708 **Table 2.** Geometric mean ratio (GMR) (95% confidence interval) of spatially weighted calcium scores (SWCS) by levels ($\mu\text{g/g}$)
709 creatinine) of non-essential and essential metals in urine. Model 1 was adjusted for age, sex, race and ethnicity, study site,
710 education, eGFR, smoking status, pack-years, physical activity and BMI. Model 2 was additionally adjusted for systolic blood
711 pressure, antihypertensive medication, LDL-cholesterol, HDL-cholesterol, lipid lowering medications, and diabetes status.

		Baseline Association		Annual Change		10 Years of Follow-up	
Non-Essential Metals		Model 1	Model 2	Model 1	Model 2	Model 1	Model 2
Cadmium, Cd	N						
Q1 [0.02, 0.35 $\mu\text{g/g}$]	1,606	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 [0.35, 0.53]	1,611	0.94 (0.79, 1.12)	0.96 (0.81, 1.15)	1.00 (0.98, 1.02)	1.00 (0.98, 1.02)	0.94 (0.80, 1.12)	0.98 (0.83, 1.15)
Q3 [0.53, 0.79]	1,600	1.20 (1.00, 1.45)	1.22 (1.01, 1.47)	0.99 (0.97, 1.01)	0.99 (0.97, 1.01)	1.06 (0.90, 1.27)	1.07 (0.91, 1.27)
Q4 [0.79, 24.29]	1,601	1.50 (1.30, 1.73)	1.51 (1.32, 1.74)	1.01 (0.99, 1.04)	1.01 (0.99, 1.04)	1.71 (1.44, 2.04)	1.75 (1.47, 2.07)
p75 vs p25	6,418	1.29 (1.14, 1.47)	1.30 (1.15, 1.47)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	1.32 (1.02, 1.70)	1.33 (1.03, 1.71)
Tungsten, W							
Q1 [0.01, 0.04 $\mu\text{g/g}$]	1,604	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 [0.04, 0.06]	1,598	1.12 (0.94, 1.33)	1.08 (0.91, 1.29)	1.01 (0.99, 1.03)	1.01 (0.99, 1.03)	1.22 (1.04, 1.44)	1.19 (1.01, 1.40)
Q3 [0.06, 0.10]	1,610	1.04 (0.88, 1.24)	1.00 (0.84, 1.19)	1.02 (0.99, 1.04)	1.02 (0.99, 1.04)	1.22 (1.03, 1.44)	1.18 (1.00, 1.40)
Q4 [0.10, 10.73]	1,606	1.20 (1.06, 1.36)	1.13 (1.00, 1.27)	1.02 (1.00, 1.05)	1.03 (1.00, 1.05)	1.53 (1.29, 1.81)	1.45 (1.23, 1.71)
p75 vs p25	6,418	1.08 (1.00, 1.16)	1.05 (0.98, 1.14)	1.01 (1.00, 1.02)	1.01 (1.00, 1.02)	1.18 (1.00, 1.40)	1.16 (0.98, 1.37)
Uranium, U							
Q1 [0.0003, 0.003 $\mu\text{g/g}$]	1,606	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 [0.003, 0.005]	1,602	1.10 (0.93, 1.31)	1.09 (0.92, 1.29)	1.00 (0.98, 1.02)	1.00 (0.98, 1.02)	1.10 (0.94, 1.30)	1.08 (0.92, 1.27)
Q3 [0.005, 0.011]	1,607	1.02 (0.85, 1.22)	0.99 (0.83, 1.18)	1.02 (1.00, 1.04)	1.02 (1.00, 1.04)	1.27 (1.07, 1.50)	1.24 (1.05, 1.46)
Q4 [0.011, 0.654]	1,603	1.23 (1.08, 1.40)	1.17 (1.04, 1.33)	1.02 (0.99, 1.04)	1.02 (0.99, 1.04)	1.43 (1.21, 1.70)	1.39 (1.17, 1.64)
p75 vs p25	6,418	1.08 (1.00, 1.16)	1.05 (0.97, 1.13)	1.01 (1.00, 1.02)	1.01 (1.00, 1.02)	1.19 (1.02, 1.39)	1.17 (1.00, 1.37)
Essential Metals		Model 1	Model 2	Model 1	Model 2	Model 1	Model 2
Cobalt, Co	N						
Q1 [0.03, 0.28 $\mu\text{g/g}$]	1,596	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 [0.28, 0.39]	1,607	1.01 (0.85, 1.20)	1.01 (0.85, 1.20)	1.01 (0.99, 1.03)	1.01 (0.99, 1.03)	1.10 (0.93, 1.30)	1.12 (0.95, 1.31)
Q3 [0.39, 0.56]	1,606	1.26 (1.05, 1.50)	1.23 (1.03, 1.46)	1.01 (0.99, 1.03)	1.01 (0.99, 1.03)	1.34 (1.13, 1.59)	1.33 (1.13, 1.57)

Q4 [0.56, 151.89]	1,609	1.31 (1.15, 1.49)	1.29 (1.14, 1.47)	1.01 (0.99, 1.03)	1.01 (0.99, 1.04)	1.46 (1.24, 1.73)	1.47 (1.25, 1.74)
p75 vs p25	6,418	1.13 (1.01, 1.27)	1.13 (1.01, 1.26)	1.01 (0.99, 1.02)	1.01 (0.99, 1.02)	1.20 (0.93, 1.55)	1.21 (0.94, 1.56)

Copper, Cu


Q1 [3.14, 9.99 µg/g)	1,605	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 [9.99, 12.37)	1,608	1.15 (0.96, 1.37)	1.13 (0.95, 1.34)	0.98 (0.96, 1.00)	0.98 (0.96, 1.00)	0.97 (0.82, 1.14)	0.94 (0.80, 1.11)
Q3 [12.37, 15.66)	1,624	1.22 (1.01, 1.46)	1.14 (0.95, 1.36)	0.99 (0.97, 1.01)	0.99 (0.97, 1.01)	1.06 (0.89, 1.26)	0.99 (0.84, 1.17)
Q4 [15.66, 1733.75]	1,581	1.36 (1.20, 1.55)	1.15 (1.01, 1.31)	1.01 (0.99, 1.04)	1.01 (0.99, 1.04)	1.55 (1.30, 1.84)	1.33 (1.12, 1.58)
p75 vs p25	6,418	1.11 (0.95, 1.30)	1.03 (0.88, 1.21)	1.01 (0.99, 1.03)	1.01 (0.99, 1.03)	1.18 (0.83, 1.68)	1.11 (0.78, 1.59)

Zinc, Zn


Q1 [11.1, 358 µg/g)	1,620	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 [358, 532)	1,613	1.20 (1.01, 1.43)	1.16 (0.98, 1.38)	1.00 (0.98, 1.02)	1.00 (0.98, 1.03)	1.24 (1.06, 1.46)	1.21 (1.03, 1.42)
Q3 [532, 802)	1,599	1.31 (1.10, 1.56)	1.16 (0.98, 1.38)	1.00 (0.98, 1.02)	1.00 (0.98, 1.02)	1.28 (1.08, 1.51)	1.14 (0.97, 1.35)
Q4 [802, 14700]	1,586	1.84 (1.62, 2.08)	1.54 (1.36, 1.74)	1.00 (0.98, 1.02)	1.00 (0.98, 1.02)	1.85 (1.56, 2.19)	1.57 (1.33, 1.85)
p75 vs p25	6,418	1.29 (1.17, 1.42)	1.19 (1.08, 1.31)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	1.26 (1.02, 1.55)	1.17 (0.95, 1.44)

712
713

714 **Figure 1.** Median and interquartile ranges [25th, 75th] of urine metal levels (µg/g creatinine) by participant characteristic for non-
 715 essential metals cadmium (Cd), tungsten (W), and uranium (U), and essential metals cobalt (Co), copper (Cu), and zinc (Zn). Points
 716 represent the median urine metal level and lines correspond to the interquartile range overall and for each subgroup at baseline. The
 717 n for each group is on the y-axis. The dotted line represents the overall median urine metal level.



719 **Figure 2.** Geometric mean ratio (GMR) (95% confidence interval) of spatially weighted calcium
720 scores (SWCS) at baseline (blue lines and shaded areas) and at 10-years of follow-up (orange
721 lines and shaded areas) by urinary metal levels ($\mu\text{g/g}$ creatinine) modeled as restricted cubic
722 splines. Lines (shaded areas) represent the GMR (95%CI) of SWCS by metals modeled as
723 restricted cubic splines for log transformed metal distributions with knots at 10th, 50th, and 90th
724 percentiles. The reference value was set at the 10th percentile. Models were adjusted for age,
725 sex, race and ethnicity, study site, education, eGFR, smoking status, pack-years, physical
726 activity, BMI, systolic blood pressure, antihypertensive medication, LDL-cholesterol, HDL-
727 cholesterol, lipid lowering medications, and diabetes status. The histograms in the background
728 represent the distribution of each metal ($\mu\text{g/g}$ creatinine) at baseline.
729



730
731